2020 Collection

Evaluation Of a New Glucose Control Strategy Using CITSens Bio APC (Automated Process Control) for CHO Fed-Batch Application

by

For the cultivation of cells in research and development, high cell densities and reproducibility are fundamental aims. For that goal a high degree of automation is favorable to reduce the risk of contamination and deviation between batches. As glucose is one of the main energy sources for cells, it is crucial to maintain a constant and controlled automated glucose supply. Therefore, the CITSens Bio APC a combined system to measure and control the glucose concentration in cell culture applications was…

October 21, 2020

High Productivity and Process Economy in GxP Applications with the Octet™ Platform

by , , and

Using the label-free optical technique of Bio-Layer Interferometry (BLI), the Octet platform provides real-time analysis of molecular interactions. It relies on the robust and easy-to-use Dip and Read™ format, which provides faster time to results relative to technologies like ELISA and SPR. It also operates in a fluidics-free format, thereby minimizing the complexity in analyte detection by fluidics-based technologies like SPR. It provides high-throughput analysis, with the option of analyzing to 96 samples simultaneously, thereby increasing analytical productivity. It has…

August 10, 2020

Accelerate Cell and Gene Therapy Development and Manufacturing with Fully Integrated Closed CAR-T Cell Therapy Platform

by

For many years, the primary forms of cancer treatment have been chemotherapy, radiation, and surgery. An amazing breakthrough known as chimeric antigen receptor (CAR) T-cell therapy is being studied in the treatment of various types of cancer, including acute and chronic lymphoblastic leukemia, non-Hodgkin lymphoma, myeloma, and solid tumors. Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Therapies recently announced the expansion of its service capabilities by offering a fully integrated…

July 15, 2020

Characterization Platform for Structural and Functional Feature Investigation of Bispecific Molecules

by

Bispecific antibodies (BsAbs ) bind to two or more targets which could be different antigens or different epitopes. Structurally, one type of bispecific antibody is similar to an IgG which contains an Fc region, and other bispecifics do not have an Fc region and typically have a relatively small molecular weight. Therefore, the characterization for a bispecific is more challenging than for a typical monoclonal antibody because of this variation in structure. The poster here discusses a set of platform…

March 31, 2020

Automated Cell Line Development With Greater Than 99% Monoclonality On the Beacon® Platform

by

For all cell lines used in production for commercial therapeutics, FDA guidelines require assurance of monoclonality. This standard means that typical cell line development (CLD) campaigns often require multiple rounds of cloning easily spanning several weeks to months. However, Berkeley Lights, Inc. (BLI) has developed the ability to save time and money spent on CLD processes via automation. The uniquely powerful Beacon® optofluidic platform performs single-cell cloning, growth and titer measurements, and recovery of top clones with unrivaled (>99%) monoclonality…

February 5, 2020